QQQ   415.94 (-1.76%)
AAPL   165.04 (-1.20%)
MSFT   399.88 (-1.09%)
META   482.06 (-3.93%)
GOOGL   153.91 (-1.35%)
AMZN   174.56 (-2.60%)
TSLA   147.73 (-1.47%)
NVDA   782.23 (-7.62%)
AMD   147.03 (-5.19%)
NIO   3.82 (-4.50%)
BABA   68.94 (+0.09%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.86 (-4.53%)
GE   148.58 (-2.85%)
CGC   8.06 (+2.94%)
DIS   112.30 (-0.12%)
AMC   3.19 (+9.25%)
PFE   25.90 (+2.01%)
PYPL   62.02 (-0.13%)
XOM   119.91 (+1.17%)
QQQ   415.94 (-1.76%)
AAPL   165.04 (-1.20%)
MSFT   399.88 (-1.09%)
META   482.06 (-3.93%)
GOOGL   153.91 (-1.35%)
AMZN   174.56 (-2.60%)
TSLA   147.73 (-1.47%)
NVDA   782.23 (-7.62%)
AMD   147.03 (-5.19%)
NIO   3.82 (-4.50%)
BABA   68.94 (+0.09%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.86 (-4.53%)
GE   148.58 (-2.85%)
CGC   8.06 (+2.94%)
DIS   112.30 (-0.12%)
AMC   3.19 (+9.25%)
PFE   25.90 (+2.01%)
PYPL   62.02 (-0.13%)
XOM   119.91 (+1.17%)
QQQ   415.94 (-1.76%)
AAPL   165.04 (-1.20%)
MSFT   399.88 (-1.09%)
META   482.06 (-3.93%)
GOOGL   153.91 (-1.35%)
AMZN   174.56 (-2.60%)
TSLA   147.73 (-1.47%)
NVDA   782.23 (-7.62%)
AMD   147.03 (-5.19%)
NIO   3.82 (-4.50%)
BABA   68.94 (+0.09%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.86 (-4.53%)
GE   148.58 (-2.85%)
CGC   8.06 (+2.94%)
DIS   112.30 (-0.12%)
AMC   3.19 (+9.25%)
PFE   25.90 (+2.01%)
PYPL   62.02 (-0.13%)
XOM   119.91 (+1.17%)
QQQ   415.94 (-1.76%)
AAPL   165.04 (-1.20%)
MSFT   399.88 (-1.09%)
META   482.06 (-3.93%)
GOOGL   153.91 (-1.35%)
AMZN   174.56 (-2.60%)
TSLA   147.73 (-1.47%)
NVDA   782.23 (-7.62%)
AMD   147.03 (-5.19%)
NIO   3.82 (-4.50%)
BABA   68.94 (+0.09%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.86 (-4.53%)
GE   148.58 (-2.85%)
CGC   8.06 (+2.94%)
DIS   112.30 (-0.12%)
AMC   3.19 (+9.25%)
PFE   25.90 (+2.01%)
PYPL   62.02 (-0.13%)
XOM   119.91 (+1.17%)
Free Trial
CVE:COT

Cotinga Pharmaceuticals Inc. (COT.V) (COT) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)
Free COT Stock Alerts
C$0.04
-0.03 (-41.67%)
(As of 10/14/2020)
Compare
Today's Range
C$0.04
▼
C$0.04
50-Day Range
C$0.04
▼
C$0.04
52-Week Range
C$0.02
▼
C$0.12
Volume
1,000 shs
Average Volume
20,281 shs
Market Capitalization
C$769,510.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis

About Cotinga Pharmaceuticals Inc. (COT.V)

Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.

COT Stock Price History

COT Stock News Headlines

February 14, 2024 | wsj.com
Lexicon Pharmaceuticals Inc.
November 5, 2023 | morningstar.com
Acumen Pharmaceuticals Inc ABOS
April 19, 2024 | Stansberry Research (Ad)
Strange new buyer driving up gold
One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."
July 22, 2023 | seekingalpha.com
SXTP 60 Degrees Pharmaceuticals, Inc.
April 28, 2023 | marketwatch.com
8-K: ENANTA PHARMACEUTICALS INC
February 18, 2023 | seekingalpha.com
Ironwood Pharmaceuticals, Inc. 2022 Q4 - Results - Earnings Call Presentation
January 24, 2023 | seekingalpha.com
PTPI Petros Pharmaceuticals, Inc.
October 11, 2022 | wsj.com
Amylyx Pharmaceuticals Inc.
April 19, 2024 | Stansberry Research (Ad)
Strange new buyer driving up gold
One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."
August 12, 2022 | yahoo.com
PepGen Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
May 26, 2022 | finance.yahoo.com
Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference
See More Headlines
Receive COT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cotinga Pharmaceuticals Inc. (COT.V) and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
CVE
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
CVE:COT
CUSIP
N/A
CIK
N/A
Web
cotingapharma.com
Phone
+1-519-8585157
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.05
Quick Ratio
0.01

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
C$0.00 per share
Price / Cash Flow
17.50
Book Value
C($0.18) per share
Price / Book
-0.20

Miscellaneous

Outstanding Shares
21,986,000
Free Float
N/A
Market Cap
C$769,510.00
Optionable
Not Optionable
Beta
N/A
These 7 Stocks Will Be Magnificent in 2024 Cover
These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Ms. Alison D. Silva
    CEO, Pres & Director
  • Dr. Richard T. Ho (Age 58)
    Chief Scientific Officer
    Comp: $323.16k
  • Mr. Victor Hugo C.M.A. (Age 51)
    C.P.A., Chief Financial Officer
  • Mr. Paul Papi
    VP of Investor Relations

Key Competitors

View All Competitors

COT Stock Analysis - Frequently Asked Questions

How have COT shares performed in 2024?

Cotinga Pharmaceuticals Inc. (COT.V)'s stock was trading at C$0.04 on January 1st, 2024. Since then, COT stock has increased by 0.0% and is now trading at C$0.04.
View the best growth stocks for 2024 here.

Is Cotinga Pharmaceuticals Inc. (COT.V) a good dividend stock?

Cotinga Pharmaceuticals Inc. (COT.V) (CVE:COT) pays an annual dividend of C$0.24 per share and currently has a dividend yield of 0.00%.

What other stocks do shareholders of Cotinga Pharmaceuticals Inc. (COT.V) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cotinga Pharmaceuticals Inc. (COT.V) investors own include Cascades (CAS), Aurora Cannabis (ACB), Advantage Lithium Corp. (AAL.V) (AAL), InPlay Oil (IPO), Harvest One Cannabis (HVT), Exchange Income (EIF), Datametrex AI (DM), Canadian National Railway (CNI) and Alimentation Couche-Tard (ATD.B).

How do I buy shares of Cotinga Pharmaceuticals Inc. (COT.V)?

Shares of COT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (CVE:COT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The A.I. story nobody is telling you (Read ASAP)
TradeSmith
The “Perfect Storm” for Gold
Gold Safe Exchange
Strange new buyer driving up gold
Stansberry Research
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
Your Money is Not Safe
American Alternative
SHOCKING Crypto Leak…
Crypto 101 Media
Top 5 AI Stocks to Buy for 2024
Market Moving Trends